DFI analysis showed that PDGFRB was a risk factor for PAAD, KIRP, and CESC patients; PFI analysis showed that PDGFRB was a risk factor for GBMLGG, KIRP, UVM, KIPAN, LGG, KICH, PAAD, MESO, BLCA patients. This evidence concerns the gene PDGFRB and pancreatic adenocarcinoma.